Rocket Pharmaceuticals withdraws US application of gene therapy for rare blood disorder
03/10/2025 12:09
Oct 3 (Reuters) - Rocket Pharmaceuticals RCKT.O said on Friday that it has withdrawn its application for U.S approval of its experimental gene therapy for a rare inherited blood disorder. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Vijay Kishore) ((Padmanabhan.Ananthan@thomsonreuters.com;))
Recent news on Rocket Pharmaceuticals
See all newsRocket Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Rocket Pharmaceuticals, Inc. expected to post a loss of 42 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
Rocket Pharmaceuticals posts Q2 profit helped by PRV sale
Brief: Rocket Pharmaceuticals Q2 EPS USD 1.08